ABEONA THERAPEUTICS INC.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Jun 2025 | Jun 2023 | Jun 2022 | Mar 2022 | Sep 2020 | Jun 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $11.4M | $8.7M | $400.0K | $3.5M | $1.0M | $346.0K | $7.0M | $0 |
| Cost of Revenue | $4.2M | $2.7M | — | — | — | — | — | — |
| Gross Profit | $7.2M | $6.0M | — | — | — | — | — | — |
| Gross Margin | 63.3% | 69.1% | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $5.0M | $9.6M | $5.9M | $8.5M | $6.7M | $10.5M | $8.0M | $16.3M |
| SG&A Expense | $15.8M | $19.5M | $17.1M | $5.0M | $3.5M | $4.2M | $4.4M | $5.6M |
| Operating Income | $-13.7M | $-23.0M | $-22.8M | $-10.6M | $-8.0M | $-20.6M | $-6.2M | $-24.0M |
| Operating Margin | -120.0% | -264.1% | -5,698.0% | -301.5% | -800.8% | -5,951.2% | -89.3% | — |
| Interest Expense | $696.0K | $830.0K | $957.0K | $103.0K | $200.0K | $201.0K | $1.3M | — |
| Pretax Income | $-20.2M | $-17.1M | $124.3M | — | — | — | — | — |
| Income Tax Expense | — | $2.0K | $15.5M | — | — | — | — | — |
| Net Income | $-20.2M | $-17.1M | $108.8M | $-16.7M | $-4.1M | $-22.0M | $-7.2M | $-23.9M |
| Net Margin | -177.4% | -195.8% | 27,208.3% | -475.8% | -409.7% | -6,371.1% | -103.4% | — |
| EPS (Basic) | $-0.35 | $-0.30 | $2.07 | $-0.31 | $0.45 | $-1.27 | $-0.03 | $-0.16 |
| EPS (Diluted) | $-0.35 | $-0.30 | $1.71 | $-0.31 | $0.45 | — | $-0.03 | $-0.16 |
| Shares Outstanding (Basic) | 57.0M | 56.6M | 52.5M | 54.1M | 17.4M | 17.4M | 253.5M | 147.7M |
| Shares Outstanding (Diluted) | 57.0M | 56.6M | 66.6M | 54.1M | 17.4M | 17.4M | 253.5M | 147.7M |
| Dividends Per Share | — | — | — | — | — | — | — | — |